Publications (345) MARIA ISABEL LUCENA GONZALEZ publications View referenced research data.

filter_list

2026

  1. An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury

    Journal of Extracellular Vesicles, Vol. 15, Núm. 3

  2. Clinical course and prognostic risk factors of SARS-CoV-2 vaccine-related hepatitis: differentiating severe acute respiratory syndrome coronavirus 2 vaccine-associated liver injury from autoimmune hepatitis

    European Journal of Gastroenterology and Hepatology, Vol. Publish Ahead of Print

  3. HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones

    Liver International, Vol. 46, Núm. 6

  4. Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool

    Acta Pharmaceutica Sinica B

  5. The gut–liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system

    Acta Pharmaceutica Sinica B

  6. Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury

    eBioMedicine, Vol. 126

2025

  1. Advancing clinical research in the Spanish primary care service: Challenges, opportunities, and lessons from other European models

    European Journal of General Practice, Vol. 31, Núm. 1

  2. Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network

    Clinical Gastroenterology and Hepatology, Vol. 23, Núm. 1, pp. 89-102

  3. Epigenetic modifications in drug-induced liver injury: A systematic review

    British Journal of Clinical Pharmacology

  4. Epigenetic modifications in drug-induced liver injury: A systematic review

    British journal of clinical pharmacology, Vol. 91, Núm. 6, pp. 1660-1674

  5. Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 21, Núm. 8, pp. 1001-1008

  6. Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population

    Liver International, Vol. 45, Núm. 2

  7. Hepatotoxicidad y nefrotoxicidad por medicamentos

    Velázquez, farmacología básica y clínica (Editorial Médica Panamericana), pp. 1221-1234

  8. Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors

    Comprehensive Toxicology (Elsevier), pp. Vol10:666-Vol10:697

  9. Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD)

    British Journal of Pharmacology, Vol. 182, Núm. 21, pp. 5303-5316

  10. Methods for causality assessment of idiosyncratic drug-induced liver injury

    Liver International, Vol. 45, Núm. 3

  11. Reply to: Correspondence on ‘Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network’

    Journal of Hepatology

  12. Sex/gender differences in clinical pharmacology: A perspective from the IUPHAR World Smart Medication Day 2025

    Pharmacological Research

  13. Short communication: miRNA122 interrogation via PCR-Free method to track liver recovery

    PLoS ONE, Vol. 20, Núm. 5 May

  14. Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at Presentation

    Journal of Clinical and Experimental Hepatology, Vol. 15, Núm. 3